首都医科大学学报 ›› 2010, Vol. 31 ›› Issue (2): 280-281.

• 临床研究 • 上一篇    下一篇

小剂量重组组织型纤维溶酶原激活剂治疗急性心肌梗死的疗效观察

丁顺晶1, 李燕2   

  1. 1. 首都医科大学附属北京天坛医院心血管内科;2. 河北医科大学附属唐山工人医院心内科
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2010-04-21 发布日期:2010-04-21

Therapeutic Effect of Low-dose Recombinant Tissue-type Plasminogen Activator on Acute Myocardial Infarction

DING Shun-jin1, LI Yan2   

  1. 1. Department of Cardiovascular Internal Medicine, Beijing Tiantan Hospital, Capital Medical University;2. Department of Cardiovascular, Tangshan Worker’s Hospital, Hebei Medical University
  • Received:1900-01-01 Revised:1900-01-01 Online:2010-04-21 Published:2010-04-21

摘要:

目的 观察重组组织型纤维蛋白激活剂栓体舒(recombinant tissue plasminogen activator,rTPA)在急性心肌梗死治疗中的临床疗效和不良反应。方法 小剂量重组组织型纤维蛋白溶酶激活剂(栓体舒)50 mg于90 min内静脉注入,治疗急性心肌梗死患者72例,观察血管再通的临床指标、不良反应及病死率。结果 梗死相关血管再灌注率75%,6周病死率4.17%,出血发生率14.17%。结论 小剂量栓舒静脉溶栓治疗急性心肌梗死较安全有效。

关键词: 急性心肌梗死, 重组组织型纤维蛋白溶酶原激活剂, 溶栓治疗

Abstract:

Objective To evaluate the therapeutic effect of recombinant tissuetype plasminogen activator(rTPA) on acute myocardial infarction. Methods 72 cases with acute myocardial infarction were treated by lowdose rTPA(50 mg) through 90 min vein injection, the clinic values of blood vessels recanalization, side effects and mortality were observed. Results Reperfusion rate of infarct related vessels was 75%, sixweek mortality was 4.17%, bleeding rate was 14.17%. Conclusion It is safe and efficient of low-dose rTPA on acute myocardial infarction.

Key words: acute myocardial infarction, recombinant tissue plasminogen activator, thrombolytic therapy

中图分类号: